Држава: Канада
Језик: Енглески
Извор: Health Canada
ERTUGLIFLOZIN; SITAGLIPTIN (SITAGLIPTIN PHOSPHATE)
MERCK CANADA INC
A10BD
COMBINATIONS OF ORAL BLOOD GLUCOSE LOWERING DRUGS
15MG; 100MG
TABLET
ERTUGLIFLOZIN 15MG; SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 100MG
ORAL
30
Prescription
DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS
Active ingredient group (AIG) number: 0260270002; AHFS:
CANCELLED POST MARKET
2021-02-03
_ _ _STEGLUJAN_™_ (ertugliflozin and sitagliptin tablets)_ _ _ _Page 1 of 52 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION STEGLUJAN™ ertugliflozin and sitagliptin tablets 5 mg/100 mg and 15 mg/100 mg ertugliflozin/sitagliptin (as sitagliptin phosphate), tablets, oral ATC Code: A10BD24 Combinations of oral blood glucose lowering drugs Merck Canada Inc. 16750 route Transcanadienne Kirkland, QC Canada H9H 4M7 www.merck.ca Date of Preparation: May 22, 2018 Submission Control No: 201006 _ _ _STEGLUJAN_™_ (ertugliflozin and sitagliptin tablets)_ _ _ _Page 2 of 52 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................4 1 INDICATIONS ...................................................................................................................4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................5 4 DOSAGE AND ADMINISTRATION ..............................................................................5 4.1 Dosing Considerations ............................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 5 4.3 Administration ......................................................................................................... 6 4.4 Reconstitution .......................................................................................................... 6 4.5 Missed Dose ............................................................................................................ 7 5 OVERDOSAGE ............ Прочитајте комплетан документ